Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillatio...
Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
About this item
Full title
Author / Creator
Shibata, Naoki, MD , Morishima, Itsuro, MD, PhD , Okumura, Kenji, MD, PhD , Morita, Yasuhiro, MD , Takagi, Kensuke, MD , Yoshida, Ruka, MD , Nagai, Hiroaki, MD , Tomomatsu, Toshiro, MD , Ikai, Yoshihiro, MD , Terada, Kazushi, MD , Tsuzuki, Kazuhito, MD , Tsuboi, Hideyuki, MD, PhD , Sone, Takahito, MD, PhD and Murohara, Toyoaki, MD, PhD
Publisher
Japan: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Japan: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Abstract Background Anticoagulation therapy with the vitamin K antagonist (VKA) warfarin has been demonstrated to reduce thromboembolic risk after electrical cardioversion (ECV). However, data concerning ECV with non-VKA oral anticoagulants (NOACs) is limited. The objective of this study was to determine the efficacy and safety of NOACs in patients...
Alternative Titles
Full title
Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
Authors, Artists and Contributors
Author / Creator
Morishima, Itsuro, MD, PhD
Okumura, Kenji, MD, PhD
Morita, Yasuhiro, MD
Takagi, Kensuke, MD
Yoshida, Ruka, MD
Nagai, Hiroaki, MD
Tomomatsu, Toshiro, MD
Ikai, Yoshihiro, MD
Terada, Kazushi, MD
Tsuzuki, Kazuhito, MD
Tsuboi, Hideyuki, MD, PhD
Sone, Takahito, MD, PhD
Murohara, Toyoaki, MD, PhD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f3f4fcd6554049888e0937780c06d89d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f3f4fcd6554049888e0937780c06d89d
Other Identifiers
ISSN
1880-4276
E-ISSN
1883-2148
DOI
10.1016/j.joa.2016.04.003
